Research graph
References from Prophylactic folinic acid prevents pemetrexed myelosuppression: A randomized trial toward safer treatment with chemotherapy in non-small cell lung cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy
2002 · External reference
Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study
10.1200/jco.22.01989 · 2023 · External reference
Non-small-cell lung cancer
10.1038/s41572-024-00551-9 · 2024 · External reference
Unresolved reference
External reference
Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC
10.1056/nejmoa2306434 · 2023 · External reference
Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC
10.1016/j.jtho.2020.09.015 · 2021 · External reference
Management and prevention of pemetrexed-related toxicity
10.1007/s40264-021-01135-2 · 2021 · External reference
Renal toxicity from Pemetrexed and Pembrolizumab in the era of combination therapy in patients with metastatic nonsquamous cell NSCLC
10.1016/j.jtho.2020.04.021 · 2020 · External reference
Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189
10.1016/j.lungcan.2021.02.021 · 2021 · External reference
Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: a prospective cohort study
10.1016/j.ejca.2019.08.012 · 2019 · External reference
Cumulative pemetrexed dose increases the risk of nephrotoxicity
10.1016/j.lungcan.2020.05.022 · 2020 · External reference
Unresolved reference
External reference
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
10.1200/jco.2003.11.136 · 2003 · External reference
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
10.1200/jco.2007.15.0375 · 2008 · External reference
Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials
10.1200/jco.2008.19.4522 · 2009 · External reference
Toxicity of pemetrexed during renal impairment explained – implications for safe treatment
2021 · External reference
Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer
10.1056/nejmoa1801005 · 2018 · External reference
The pharmacoeconomic benefits of pemetrexed dose individualization in patients with lung cancer
10.1002/cpt.2529 · 2022 · External reference
Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514
1998 · External reference
A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase
10.1021/jm00101a023 · 1992 · External reference
Leucovorin rescue from raltitrexed (tomudex)-induced antiproliferative effects: in vitro cell line and in vivo mouse studies
2000 · External reference
10.1002/cpt.3735
10.1002/cpt.3735 · External reference
Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer
10.1093/annonc/mdf115 · 2002 · External reference
A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate
1998 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Lansoprazole exacerbates pemetrexed-mediated hematologic toxicity by competitive inhibition of renal basolateral Human organic anion transporter 3
10.1124/dmd.116.070722 · 2016 · External reference
Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: the prospective IPPEM study
10.1016/j.lungcan.2022.02.007 · 2022 · External reference
LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes
1997 · External reference
Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis
1999 · External reference
Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma
10.1097/jto.0b013e318283da3e · 2013 · External reference
Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management
10.1002/cncr.11882 · 2004 · External reference
Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy
10.1002/cncr.20983 · 2005 · External reference
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia
10.7326/0003-4819-64-2-328 · 1966 · External reference
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs
10.1200/jco.2002.02.140 · 2002 · External reference
A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy
10.1007/s00280-005-0077-5 · 2006 · External reference
Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial
10.7326/0003-4819-121-7-199410010-00004 · 1994 · External reference
Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
10.1186/1471-2407-13-386 · 2013 · External reference
Targeting anemia in patients with lung cancer
2006 · External reference
Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: a retrospective cohort study
10.1371/journal.pone.0171066 · 2017 · External reference
Unresolved reference
External reference
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
10.1016/j.ejca.2010.10.013 · 2011 · External reference
